Network Pharmacology and Experimental Validation of the Anti-Inflammatory Effect of Tingli Dazao Xiefei Decoction in Acute Lung Injury Treatment
Chengxi Zhang,Xiaoqian Li,Dan Gao,Huahe Zhu,Shun Wang,Bo Tan,Aidong Yang
DOI: https://doi.org/10.2147/jir.s433840
IF: 4.5
2023-12-20
Journal of Inflammation Research
Abstract:Chengxi Zhang, 1, 2 Xiaoqian Li, 1, 2 Dan Gao, 1, 2 Huahe Zhu, 3 Shun Wang, 1, 2 Bo Tan, 4 Aidong Yang 1, 2 1 School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 2 Center for Traditional Chinese Medicine and Epidemic Disease, Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, People's Republic of China; 3 Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, People's Republic of China; 4 Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China Correspondence: Aidong Yang; Bo Tan, Tel +86-21-135 6482 0109 ; +86-21-137 6418 9001, Fax +86-21-51322141 ; +86-21-20256699, Email ; Purpose: Tingli Dazao Xiefei Decoction (TDXD) is a Traditional Chinese Medicine (TCM) formula used to treat acute lung injury (ALI). However, the precise mechanism of TDXD in treating ALI remains unclear. We investigated the therapeutic mechanism of TDXD against ALI using a complementary approach combining network pharmacology, molecular docking, and in vitro and in vivo experiments. Material and Methods: Potential drug targets of TDXD and relevant target genes associated with ALI were retrieved from Chinese medicines and disease genes databases. Bioinformatics technology was employed to screen potential active ingredients and core targets. Validation experiments were conducted using a lipopolysaccharide (LPS)-induced ALI mouse (C57BL/6J) model, LPS-induced inflammatory RAW264.7 cells, and molecular docking between active compounds of TDXD and potential targets. Results: Network pharmacology suggested that the mechanism of TDXD against ALI involved phosphoinositide 3-kinase (PI3K) / protein kinase B (AKT) / phosphatase and tensin homolog (PTEN) and Janus kinase 2 (JAK2) / signal transducer and activator of transcription 3 (STAT3) pathways. Quercetin, β-sitosterol, kaempferol, isorhamnetin, and L-stepholidine were identified as the main active compounds of TDXD that exerted anti-ALI effects. Molecular docking indicated that these compounds exhibited good binding capabilities (≤ − 5kcal/mol) to key targets in PI3K/AKT/PTEN and JAK2/STAT3 signaling pathways. In the animal model, TDXD alleviated injuries and inflammatory responses in lung tissues, accompanied by inhibition of expression of tumor necrosis factor-α (TNF-α), Interleukin-6 (IL-6), STAT3, and Suppressor of Cytokine Signaling 3 (SOCS3) mRNA, and key proteins in PI3K/AKT/PTEN and JAK2/STAT3 pathways (all P values < 0.05). Cell based experiments showed that TDXD dose-dependently inhibited the expression of essential proteins in PI3K/AKT/PTEN and JAK2/STAT3 pathways (P < 0.05). Conclusion: This study revealed that the mechanism of TDXD in ALI treatment might involve simultaneous regulation of PI3K/AKT/PTEN and JAK2/STAT3 pathways. Keywords: network pharmacology, molecular docking, lipopolysaccharide, PI3K/AKT/PTEN, JAK2/STAT3 Acute lung injury (ALI) is a clinical syndrome characterized by acute progressive respiratory distress and refractory hypoxemia. The main manifestations of ALI include increased alveolar-capillary membrane permeability, edema, and diffuse alveolar injury. 1 ALI can progress to acute respiratory distress syndrome (ARDS) and cause significant morbidity and mortality. 2,3 This is one of the critical reasons why patients are transferred to an intensive care unit and have a 40% fatality rate. 4 The pathogenesis of ALI/ARDS primarily includes pulmonary infection, pulmonary contusion, sepsis, etc., among which infection is the most common cause. 5,6 Owing to the pathogenetic heterogeneity of ALI, effective treatments are lacking in clinical practice and adjuvant therapies, such as respiratory ventilation and symptomatic drugs, are typically used. 6,7 Therefore, there is an urgent need to thoroughly investigate the pathophysiologic mechanisms of ALI progression to identify improved prognostic and therapeutic targets. Studies have shown that inflammatory infiltration and hyperplasia of pulmonary microvascular endothelial cells induced by inflammatory factors, are essential pathogeneses of ALI. 8 Thus, inhibiting the activity of inflammatory effect can prevent and mitigate ALI/ARDS. Traditional Chinese Medicine (TCM) has a long history of having unique advantages for treating various diseases, including ALI. 9 Tingli Dazao Xiefei Decoction (TDXD) is a TCM classical prescription treatment for lung diseases and consists of two her -Abstract Truncated-
immunology